Olumniant (Baricitinib) oral tablets: An insight into FDA-approved systemic treatment for Alopecia Areata

Eman Ali; Rabia Owais; Ayesha Sheikh; Asim Shaikh

doi:10.1016/j.amsu.2022.104157

Olumniant (Baricitinib) oral tablets: An insight into FDA-approved systemic treatment for Alopecia Areata

Ann Med Surg (Lond). 2022 Jul 13:80:104157. doi: 10.1016/j.amsu.2022.104157. eCollection 2022 Aug.

Authors

Eman Ali¹, Rabia Owais¹, Ayesha Sheikh¹, Asim Shaikh¹

Affiliation

¹ Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan.

Abstract

Olumniant (Barcitinib) has gained swift approval by the Food and Drug Administration (FDA) as a promising medication for the treatment of adults with severe Alopecia Areata. This drug has proven to be effective for various conditions including Covid-19 and Rheumatoid Arthritis as well as being found to be less costly and minimally invasive, with no need for post-operative management. However, its use has some considerable potential implications before its prescription can be made commonplace. Therefore, more trials need to be conducted to establish a more rigid safety profile.

Keywords: Alopecia Areata; FDA-Approved; Olumniant (Baricitinib).